FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1843978583> ?p ?o ?g. }

• W1843978583 endingPage "942" @default.
• W1843978583 startingPage "936" @default.
• W1843978583 abstract "Raltegravir (RAL) is the only licensed human immunodeficiency virus (HIV) integrase inhibitor. The factors associated with the virological response to RAL-containing regimens and the prevalence of integrase mutations associated with RAL failure deserve further investigation. From the Antiretroviral Resistance Cohort Analysis database, we selected triple-class-experienced subjects failing their current treatment with complete treatment history available. Selection criteria included HIV-RNA, CD4 count and HIV genotype within 3 months of RAL initiation. Factors associated with 24-week response were analysed; genotypic sensitivity scores (GSS) and weighted-GSS were evaluated. Virological response was achieved in 74.3% of 105 subjects. Mutations associated with RAL failure were detected in 12/24 subjects with an integrase genotype, with the prevalence of Q148H + G140S. Each extra unit of GSS (p 0.05, OR 2.62; 95% CI 1.00–6.87). was found to be a associated with response. Weighted-GSS had borderline statistical significance (p 0.063, OR 2.04; 95% CI 0.96–4.33) When stratifying for different cut-offs (< 1 as reference, 1–1.49, ≥ 1.5), a borderline significant increase in the probability of response appeared for GSS ≥ 1.5 (p 0.053, OR 4.00; 95% CI 0.98–16.25). GSS ≥ 1 showed the highest sensitivity, 82.6%. Receiver operating characteristic curves depicted the widest area under the curve (0.663, p 0.054) of GSS ≥ 1. Unresponsiveness to RAL-containing regimens among triple-class-experienced subjects was low. The activity of the background regimen was strongly associated with response. Although few integrase genotypes were available at failure, half of these were without integrase resistance mutations. The substantial rate of RAL failure in the absence of known RAL-resistance mutations may be associated with adherence issues and this issue warrants further analysis in longer observations." @default.
• W1843978583 created "2016-06-24" @default.
• W1843978583 creator A5002187853 @default.
• W1843978583 creator A5002487044 @default.
• W1843978583 creator A5002495981 @default.
• W1843978583 creator A5014263659 @default.
• W1843978583 creator A5021259835 @default.
• W1843978583 creator A5024211201 @default.
• W1843978583 creator A5036495713 @default.
• W1843978583 creator A5039613583 @default.
• W1843978583 creator A5042651024 @default.
• W1843978583 creator A5044035449 @default.
• W1843978583 creator A5044171804 @default.
• W1843978583 creator A5053248827 @default.
• W1843978583 creator A5066390359 @default.
• W1843978583 creator A5075069140 @default.
• W1843978583 creator A5089561472 @default.
• W1843978583 date "2013-10-01" @default.
• W1843978583 modified "2023-10-14" @default.
• W1843978583 title "Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database" @default.
• W1843978583 cites W1536785903 @default.
• W1843978583 cites W1983837630 @default.
• W1843978583 cites W1988062692 @default.
• W1843978583 cites W1989218343 @default.
• W1843978583 cites W1994770156 @default.
• W1843978583 cites W2014765324 @default.
• W1843978583 cites W2015339905 @default.
• W1843978583 cites W2063321514 @default.
• W1843978583 cites W2094889034 @default.
• W1843978583 cites W2096981707 @default.
• W1843978583 cites W2102134351 @default.
• W1843978583 cites W2106866317 @default.
• W1843978583 cites W2108497544 @default.
• W1843978583 cites W2114822477 @default.
• W1843978583 cites W2124600882 @default.
• W1843978583 cites W2127237622 @default.
• W1843978583 cites W2135417699 @default.
• W1843978583 cites W2143036893 @default.
• W1843978583 cites W2145109590 @default.
• W1843978583 cites W2153467269 @default.
• W1843978583 cites W2154190260 @default.
• W1843978583 cites W2164541113 @default.
• W1843978583 doi "https://doi.org/10.1111/1469-0691.12100" @default.
• W1843978583 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23289841" @default.
• W1843978583 hasPublicationYear "2013" @default.
• W1843978583 type Work @default.
• W1843978583 sameAs 1843978583 @default.
• W1843978583 citedByCount "10" @default.
• W1843978583 countsByYear W18439785832015 @default.
• W1843978583 countsByYear W18439785832016 @default.
• W1843978583 countsByYear W18439785832017 @default.
• W1843978583 countsByYear W18439785832018 @default.
• W1843978583 countsByYear W18439785832019 @default.
• W1843978583 countsByYear W18439785832021 @default.
• W1843978583 crossrefType "journal-article" @default.
• W1843978583 hasAuthorship W1843978583A5002187853 @default.
• W1843978583 hasAuthorship W1843978583A5002487044 @default.
• W1843978583 hasAuthorship W1843978583A5002495981 @default.
• W1843978583 hasAuthorship W1843978583A5014263659 @default.
• W1843978583 hasAuthorship W1843978583A5021259835 @default.
• W1843978583 hasAuthorship W1843978583A5024211201 @default.
• W1843978583 hasAuthorship W1843978583A5036495713 @default.
• W1843978583 hasAuthorship W1843978583A5039613583 @default.
• W1843978583 hasAuthorship W1843978583A5042651024 @default.
• W1843978583 hasAuthorship W1843978583A5044035449 @default.
• W1843978583 hasAuthorship W1843978583A5044171804 @default.
• W1843978583 hasAuthorship W1843978583A5053248827 @default.
• W1843978583 hasAuthorship W1843978583A5066390359 @default.
• W1843978583 hasAuthorship W1843978583A5075069140 @default.
• W1843978583 hasAuthorship W1843978583A5089561472 @default.
• W1843978583 hasBestOaLocation W18439785831 @default.
• W1843978583 hasConcept C104317684 @default.
• W1843978583 hasConcept C114851261 @default.
• W1843978583 hasConcept C126322002 @default.
• W1843978583 hasConcept C135763542 @default.
• W1843978583 hasConcept C142462285 @default.
• W1843978583 hasConcept C14430832 @default.
• W1843978583 hasConcept C159047783 @default.
• W1843978583 hasConcept C2777302000 @default.
• W1843978583 hasConcept C2780404665 @default.
• W1843978583 hasConcept C2781413609 @default.
• W1843978583 hasConcept C2993143319 @default.
• W1843978583 hasConcept C3013748606 @default.
• W1843978583 hasConcept C54355233 @default.
• W1843978583 hasConcept C71924100 @default.
• W1843978583 hasConcept C72563966 @default.
• W1843978583 hasConcept C86803240 @default.
• W1843978583 hasConceptScore W1843978583C104317684 @default.
• W1843978583 hasConceptScore W1843978583C114851261 @default.
• W1843978583 hasConceptScore W1843978583C126322002 @default.
• W1843978583 hasConceptScore W1843978583C135763542 @default.
• W1843978583 hasConceptScore W1843978583C142462285 @default.
• W1843978583 hasConceptScore W1843978583C14430832 @default.
• W1843978583 hasConceptScore W1843978583C159047783 @default.
• W1843978583 hasConceptScore W1843978583C2777302000 @default.
• W1843978583 hasConceptScore W1843978583C2780404665 @default.
• W1843978583 hasConceptScore W1843978583C2781413609 @default.
• W1843978583 hasConceptScore W1843978583C2993143319 @default.

• next